ChronoScale Corporation Common Stock (NASDAQ:CHRN) Coverage Initiated at Northland Securities

Equities researchers at Northland Securities started coverage on shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) in a report released on Friday, Briefing.com reports. The brokerage set an “outperform” rating and a $32.00 price target on the stock. Northland Securities’ target price suggests a potential upside of 58.97% from the stock’s current price.

Separately, Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, August 24th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $19.00.

ChronoScale Corporation Common Stock Stock Performance

Shares of CHRN opened at $20.13 on Friday. The stock has a 50-day simple moving average of $21.49 and a 200-day simple moving average of $17.04. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.51 and a current ratio of 0.51. The stock has a market capitalization of $2.93 billion, a PE ratio of -3.74 and a beta of 0.98. ChronoScale Corporation Common Stock has a 1 year low of $3.50 and a 1 year high of $30.00.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its earnings results on Wednesday, August 19th. The company reported ($0.12) earnings per share for the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%.The firm had revenue of $18.40 million for the quarter. On average, analysts predict that ChronoScale Corporation Common Stock will post -0.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ChronoScale Corporation Common Stock

An institutional investor recently raised its position in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc increased its holdings in shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN) by 104.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,338 shares of the company’s stock after purchasing an additional 1,195 shares during the quarter. Roble Belko & Company Inc owned approximately 0.07% of ChronoScale Corporation Common Stock worth $25,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 6.42% of the company’s stock.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.